Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)-A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitm
about
HDL, Atherosclerosis, and Emerging TherapiesAnti-PCSK9 antibodies for hypercholesterolaemia: Overview of clinical data and implications for primary care.Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk.ANMCO/ISS/AMD/ANCE/ARCA/FADOI/GICR-IACPR/SICI-GISE/SIBioC/SIC/SICOA/SID/SIF/SIMEU/SIMG/SIMI/SISA Joint Consensus Document on cholesterol and cardiovascular risk: diagnostic-therapeutic pathway in Italy.Effect of evacetrapib on cardiovascular outcomes in patients with high-risk cardiovascular disease.Pharmacokinetics, pharmacodynamics and clinical efficacy of non-statin treatments for hypercholesterolemia.Lipid-modifying activity of curcuminoids: A systematic review and meta-analysis of randomized controlled trials.Effect of Exceptional Parental Longevity and Lifestyle Factors on Prevalence of Cardiovascular Disease in Offspring.No cardiovascular benefit with evacetrapib - is this the end of the road for the 'cetrapibs'?Time for new low density lipoprotein cholesterol (LDL-C) targets?Exercise Training Favorably Modulates Gene and Protein Expression That Regulate Arterial Cholesterol Content in CETP Transgenic Mice.
P2860
Q36918309-136748C6-7BEA-4A0E-BB7E-2FA23B218F6FQ38657213-50DE1233-0A7C-4D37-A5C5-19C47ACECFC0Q40068181-6ADDC0BC-662B-4C63-8D4C-D88EBADCACFCQ40104818-838448C8-E010-4C60-8390-EF2FC5A97A95Q42342025-E10C54EB-AEDF-458B-A24A-DDB202A246CBQ47303571-8DE90CED-1830-43AB-BB8E-D0B8287CC8DDQ47398352-E5820304-2F1A-4695-991B-4F2A74BD1527Q47648351-57B619A8-FC37-4CEF-8586-FB6D9B8AB97FQ47964648-7FF7C4D3-0439-4C75-A3A5-BDED2A18B30CQ50493131-D066A43B-92F4-4647-8DCD-BD4E4949AAC7Q55334352-A02954E7-6A61-4EB0-B5A7-23E6B01DD972
P2860
Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)-A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitm
description
2017 nî lūn-bûn
@nan
2017 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
Randomized Evaluation of the E ...... isease: Trial design, recruitm
@ast
Randomized Evaluation of the E ...... isease: Trial design, recruitm
@en
type
label
Randomized Evaluation of the E ...... isease: Trial design, recruitm
@ast
Randomized Evaluation of the E ...... isease: Trial design, recruitm
@en
prefLabel
Randomized Evaluation of the E ...... isease: Trial design, recruitm
@ast
Randomized Evaluation of the E ...... isease: Trial design, recruitm
@en
P2093
P2860
P1476
Randomized Evaluation of the E ...... , and baseline characteristics
@en
P2093
C P Cannon
E Braunwald
E Valdes- Marquez
J C Hopewell
M J Landray
REVEAL Collaborative Group
P2860
P304
P356
10.1016/J.AHJ.2017.02.021
P407
P577
2017-02-21T00:00:00Z